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T
hree randomized, controlled 
clinical trials in South Africa, 
Kenya, and Uganda were 
recently unblinded early because 
interim analyses concluded that 
circumcision of HIV-negative adult 
males reduced their risk for acquiring 
HIV infection through penile–vaginal 
sex [1–3]. In each trial, men who 
had been randomly assigned to 
an intervention group receiving 
circumcision had a lower incidence 
of HIV infection in up to two years 
of follow up, compared to men who 
were assigned to a control group not 
receiving circumcision. The estimated 
reduction in the risk of HIV infection 
ranged from 51% to 60%; per-protocol 
estimates of risk reduction ranged from 
55% to 76%.
It is now clear that male circumcision 
can be efﬁ  cacious for men in reducing 
their risk of HIV acquisition through sex 
with women [4]. Some experts predict 
that the impact of male circumcision 
as a biomedical intervention for HIV 
prevention in Africa could be large 
[5,6], and preparatory work has been 
done to establish male circumcision 
programs in Africa. The implications 
of African trials on circumcision for 
HIV prevention programs in the 
United States are less clear—despite 
the interest of the popular press in 
the idea [7]. Here, we consider the 
differences between the HIV epidemics 
in Africa and the US, the current status 
of male circumcision in the US, and 
the knowledge gaps that will need to 
be addressed as we consider whether 
male circumcision should be evaluated 
or implemented as a biomedical 
intervention to reduce sexually acquired 
HIV infections domestically.
Epidemiological Differences
The results of any trial must be 
interpreted with the caution that 
inference not be extended to 
populations differing from the study 
participants in important ways. 
The HIV epidemics in Africa are 
substantially different from the US 
epidemic. Generalized HIV epidemics 
exist in many areas of Africa, and 
the population prevalence of HIV 
among adult Kenyans, Ugandans, 
and South Africans ranges from 
6%–19% [8]. The predominant 
mode of HIV transmission in Africa is 
male–female sex. In contrast, the US 
has a concentrated epidemic, with most 
sexual transmission occurring among 
men who have sex with men (MSM). 
The general population prevalence of 
HIV is about 0.4% in the US [9], and 
only 15% of men diagnosed with HIV 
infection during 2005 were reported 
to have acquired HIV through male–
female sex [10].
Biological Plausibility of 
Circumcision to Prevent HIV 
Acquisition
The association between circumcision 
and reduced risk for HIV acquisition 
is biologically plausible: the foreskin 
contains high concentrations of 
superﬁ  cial Langerhans cells, CD4+ T 
cells, and macrophages [11]—all target 
cells for HIV infection, some of which 
may also be close to the skin surface 
[12,13]. In addition, the preputial 
sac may serve as a reservoir for HIV-
containing secretions, resulting in 
prolonged contact time after exposure 
to secretions, and the foreskin may 
present less of a physical barrier to HIV 
entry than the more heavily keratinized 
skin of the shaft of the penis [12], and 
may have more frequent epithelial 
disruption. There are also potential 
indirect mechanisms of association 
between lack of circumcision and HIV 
risk; for example, lack of circumcision 
is associated with increased risk of 
genital ulcer diseases, which in turn are 
associated with increased risk of HIV 
transmission and acquisition [14].
Considerations for Prevention 
of HIV Transmission by Penile–
Vaginal Sex in the US
Epidemic differences are important 
because, on a population basis, 
the impact of circumcision as an 
intervention to prevent HIV infection 
among men who have sex with women 
will depend on the likelihood of HIV 
exposure among such men in the US—
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and, therefore, on the prevalence of 
HIV among their female sex partners. 
A recent analysis of data from sexually 
transmitted disease clinics in Baltimore 
evaluated the association of male 
circumcision and risk of prevalent HIV 
infection in two ways—ﬁ  rst, evaluating 
all male attendees at the clinics, and 
second, restricting the analysis to 
males who were known to have been 
exposed to HIV heterosexually (e.g., 
sexual contacts of partners known to 
be infected with HIV) [15]. The results 
indicated that, while circumcision was 
not associated with lower HIV infection 
in the entire population of male STD 
clinic attendees, where HIV prevalence 
was 3%, circumcision was associated 
with signiﬁ  cantly lower HIV prevalence 
in the subset of men with a known 
infected female sex partner, where the 
group’s prevalence of infection was 
markedly higher at 12% (adjusted odds 
ratio [aOR] = 0.46; 95% conﬁ  dence 
interval [CI] 0.22–0.97). In effect, 
this analysis illustrated the impact 
of partner prevalence of HIV on the 
association of circumcision and HIV 
infection status, and concluded that it 
was difﬁ  cult to detect a protective effect 
from circumcision on HIV infection in 
the setting of a partner pool with lower 
HIV prevalence.
Considerations for Prevention of 
HIV Transmission by Male–Male 
Sex
Most sexual transmission of HIV in 
the US occurs through male–male sex 
[10], most often infecting the receptive 
partner in penile–anal intercourse 
[16]. The results from the African 
trials demonstrated that circumcision 
was protective for men who were 
the insertive partner in vaginal 
intercourse, suggesting that the utility 
of male circumcision in preventing 
HIV transmission among MSM may 
be limited. Because reducing the 
concentration of target cells for HIV 
infection on the penis is a proposed 
protective mechanism, understanding 
the relative viral challenge presented by 
vaginal versus anal–rectal secretions is 
relevant to evaluating the plausibility of 
a protective effect of circumcision for 
the insertive male partner during anal 
intercourse. The concentration of HIV 
RNA in rectal secretions may be higher 
than in blood or semen, regardless 
of use of antiretroviral therapy [17], 
and may be orders of magnitude 
higher than the concentrations in 
vaginal or cervical secretions [17,18]. 
Circumcision may change the balance 
of virus and target cells, but if rectal 
mucosal secretions contain a higher 
concentration of infectious virus 
than vaginal secretions, any potential 
protective effect of circumcision for the 
insertive partner may be overwhelmed 
by excess virus. Also, new data suggest 
that, for limited periods of time before 
wound healing is complete, female 
sex partners of newly circumcised 
HIV-infected men may be at increased 
risk of acquiring HIV [4]. Possible 
transient increased risk of transmission 
(before complete wound healing) from 
recently circumcised HIV-infected 
MSM to their receptive anal intercourse 
partners would also be of concern.
Few studies provide evidence as to 
whether circumcision may protect 
against HIV infection among MSM. 
In a vaccine preparedness cohort 
of MSM followed from 1995 to 
1997, circumcision was signiﬁ  cantly 
associated with a decreased risk for 
HIV seroconversion (aOR = 0.5; 95% 
CI 0.3–0.9), controlling for number of 
male sex partners and unprotected sex 
with an HIV-positive partner [19]. In 
a cross-sectional survey of gay men in 
Seattle in the early 1990s, circumcision 
was associated with decreased odds of 
prevalent HIV infection (aOR = 0.5; 
95% CI 0.25–1.0) [20]. While falling 
short of the quality of data from a 
randomized intervention trial, these 
limited data suggest that circumcised 
MSM in the US may have decreased 
risk of HIV infection. However, it is 
possible that the noted associations in 
these two observational studies were 
related to uncontrolled bias. A small 
cross-sectional study of Australian 
MSM found no association between 
circumcision status and risk of HIV 
infection, when stratifying by insertive 
and receptive roles [21].
Virological Issues
In the African countries where 
circumcision has been demonstrated 
to be efﬁ  cacious, the predominant 
HIV subtypes are A, C, and D; it 
is likely that some recombinant 
strains were also represented in the 
Kenya and Uganda trials. In the US, 
subtype B predominates. Despite the 
theoretical possibility that subtype 
differences in either vaginal shedding 
of HIV or afﬁ  nity to HIV receptors 
(especially those natively expressed 
on the foreskin) could modify the 
effectiveness of circumcision as an 
HIV prevention intervention, the 
consistent ﬁ  ndings of the African 
trials argue that this is unlikely. For 
example, despite differences in vaginal 
shedding between subtype C and 
subtypes A and D [18], the efﬁ  cacy of 
circumcision in trials where subtypes A, 
C, or D were prevalent was comparable. 
One potentially relevant biological 
difference relates to binding avidity 
of HIV subtypes for CCR5 receptors, 
which are important mechanisms for 
entry into Langerhans cells, and are 
the predominant HIV-1 co-receptor in 
foreskin immune cells [11]. Subtype 
WHO/UNAIDS Technical Consultation on Male Circumcision and HIV 
Prevention: Research Implications for Policy and Programming
In March 2007, the World Health Organization and the Joint United Nations 
Programme on HIV/AIDS held a technical consultation on male circumcision and issued 
a summary document providing conclusions and recommendations relating to policy 
and programming on male circumcision and HIV prevention [4]. The document hails 
the results of the three African trials as “an important landmark in the history of HIV 
prevention” and states that male circumcision should be recognized as an efﬁ  cacious 
intervention for the prevention of heterosexually acquired HIV infection in men. It was 
noted that male circumcision does not provide complete protection against HIV, and 
should always be considered as part of a comprehensive HIV prevention package. The 
document also concluded that the population level impact of male circumcision will be 
greatest in settings where the prevalence of heterosexually transmitted HIV infection 
is high, the levels of male circumcision are low, and populations at risk are large. 
Further, the document provides guidance about communication strategies, ethical 
and cultural issues, programmatic issues, ﬁ  nancing issues, and needs for supporting 
health care services in developing countries. The document also explicitly states that, 
based on limited available data, promoting circumcision for HIV-positive men is not 
recommended. The full report of the technical consultation is available at: http://www.
who.int/entity/hiv/mediacentre/MCrecommendations_en.pdf [4].
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C is reported to have lower binding 
avidity than subtype B for CCR5 
receptors [22]; it is unclear whether 
the greater binding avidity of subtype 
B for CCR5 could represent an escape 
mechanism to overcome the decreased 
availability of target cells that results 
from circumcision.
Status of Circumcision in the US
Public health recommendations 
will likely have the largest impact 
in populations where circumcision 
has been rare. Non-religious male 
circumcision was introduced to the 
US in the late 1800s [23], and by the 
1940s, an increasing proportion of 
male children in the US were born in 
hospitals and were circumcised [24]. 
The proportion of newborns that 
were circumcised annually reached 
80% after World War II and peaked 
in the mid-1960s. The proportion of 
male babies circumcised subsequently 
decreased. According to the National 
Hospital Discharge Survey, which 
documents circumcisions performed 
in hospitals but would not ascertain 
circumcisions performed outside of 
the hospital for religious reasons, 
65% of newborns were circumcised in 
1999. Although the overall proportion 
of newborns circumcised has been 
stable from 1979 to 1999 [25], the 
proportion of black newborns who 
were circumcised rose over this period 
to approximately 65%. Signiﬁ  cant 
discrepancies also exist by region. 
While the proportion of newborns born 
in the Midwest who were circumcised 
increased over the 20-year period to 
81% in 1999, the proportion of infants 
born in the West who were circumcised 
decreased over the same period, to 
37% in 1999 [25].
Data from another hospital discharge 
survey, the National Inpatient 
Sample, present a slightly different 
picture [26]. In that survey, newborn 
circumcision rates increased from 48% 
in 1988–1991, to 61% in 1997–2000. 
Circumcision was more common 
among newborns born to families of 
higher socioeconomic status, in the 
Northeast or Midwest, and among 
newborns who were black [26].
Data from the National Health 
and Nutrition Examination Surveys 
from 1999 to 2004 indicated that the 
overall prevalence of circumcision 
among adult males in the US was 79% 
and varied by race/ethnicity (88% in 
non-Hispanic white men, 73% in non-
Hispanic black men, 42% in Mexican 
Americans, and 50% in others). The 
prevalence of circumcision decreased 
among US-born men from the 1970s 
to the 1980s [27]. Although causality 
cannot be implied by these data and 
many other factors are likely operative, 
the rates of HIV and AIDS among 
non-Hispanic black and Hispanic men 
are considerably higher than in non-
Hispanic white men in the US [28].
Willingness of Adult Males to Be 
Circumcised
The ability of investigators to fully 
enroll three trials of adult circumcision 
[1–3] in Africa speaks to the 
acceptability of circumcision among 
adult males in South Africa, Kenya, 
and Uganda. A recent systematic 
review of published literature suggests 
that adult male circumcision may 
be acceptable as an HIV prevention 
intervention in many countries in sub-
Saharan Africa [29]. In the US, the 
overwhelming majority of circumcisions 
are performed on newborns; adult 
circumcisions are commonly only done 
for medical reasons, such as preputial 
cancer or phimosis. It is not clear 
whether adult circumcision, were it to 
be recommended in the US, would be 
acceptable as a prevention intervention. 
Preliminary evidence from interviews 
with uncircumcised MSM surveyed at 
Gay Pride festivals in the US suggests 
that the majority of MSM would 
consider circumcision as an adult, if 
circumcision were shown to reduce 
risk of HIV infection by male–male 
sex [30]—although respondents were 
not told in the survey that protection 
would be partial or that condom use 
would still be recommended after 
circumcision.
Policy Issues Related to 
Circumcision of Newborn Boys
The American Academy of Pediatrics 
changed from a less conclusive stance 
on circumcision in 1989 [31], which 
cited potential medical beneﬁ  ts 
and advantages (primarily reduced 
occurrence of phimosis and penile 
cancer) as well as disadvantages and 
risks, to their statement in 1999 that 
available data were not sufﬁ  cient 
to recommend routine neonatal 
circumcision [32]. The 1999 position 
was re-afﬁ  rmed in 2005 by the Academy 
after publication of the results of the 
South Africa trial [33]. In a 1995 US 
review, 61% of infant circumcisions 
were paid by private insurance, 36% 
were paid for by Medicaid, and 3% 
were self-paid by the parents of the 
infant [34]. Since 1999, 16 states have 
eliminated Medicaid payments for 
circumcisions that were not deemed 
medically necessary [35].
Should Adult Male Circumcision Be 
Recommended for HIV Prevention 
in the US?
Circumcision may have a role for the 
prevention of HIV transmission in the 
US. However, because of the many 
differences between the underlying 
HIV epidemics in Africa and the 
US, differences in the prevalence of 
male circumcision in Africa and the 
US, and the considerable gaps in 
knowledge that exist regarding the 
potential impact of circumcision on 
HIV transmission by male–male sex, 
the extent of this role on a population 
basis is unknown. Further, the already 
high prevalence of circumcision among 
US men suggests some limitations in 
the potential impact of circumcision at 
a population level.
Based on the data from the three 
African clinical trials, it is likely 
that circumcision will decrease the 
probability of a man acquiring HIV via 
penile–vaginal sex with an HIV-infected 
woman in the US. Until public health 
recommendations are available for 
the US, some sexually active men may 
consider circumcision as an additional 
HIV prevention measure, but should 
do so only in consultation with their 
physician or health care provider, 
and with a clear understanding of the 
costs and risks of circumcision and the 
need to continue use of other, proven 
prevention measures (e.g., reducing 
the numbers of sex partners and using 
condoms consistently and correctly). 
Men who choose to be circumcised 
should also be counseled about the 
importance of refraining from sexual 
intercourse following circumcision, 
until wound healing is complete [4].
To consider the possible impact of 
public health recommendations for 
male circumcision, we must also take 
into account HIV incidence in high-risk 
groups, as well as adoption of other 
protective behaviors, such as condom 
use. For example, HIV incidence among 
US MSM recruited in community- and 
venue-based samples was, on average, 
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about 1.9% annually [36], and 36% of 
MSM in the US National HIV Behavioral 
Surveillance System reported having 
unprotected anal sex with a casual 
partner in the last 12 months before 
interview [37]. There are few data 
on HIV incidence among high-risk 
heterosexuals in the US, but there are 
limited data on condom use: in 2002, 
16% of high-risk heterosexual men and 
24% of high-risk heterosexual women 
reported that they never used condoms 
during penile–vaginal sex with a non-
primary partner [38]. Currently available 
data on disparities in rates of prevalent 
HIV infection and AIDS [28,39] and the 
prevalence of circumcision among US 
men suggest that black and Hispanic 
men may have particular opportunities 
for reduction of risk of HIV acquisition 
through circumcision.
Future Research and Consultation
In order to understand the potential 
for male circumcision as an HIV 
prevention approach in the US, we 
believe that there are important 
questions that should be answered. 
These include questions that can 
be answered by basic science, by 
modeling, by surveys of acceptability, 
by considering ethical issues, and, 
perhaps, by clinical trials in the US. For 
example, it is important to understand 
more fully the differences in shedding 
of HIV by rectal versus vaginal mucosa. 
Modeling may provide important 
information on (1) the impact on 
the US epidemic from increasing 
male circumcision rates, and (2) the 
cost–beneﬁ  t ratio of circumcision 
among newborns, or among adult 
men with high risk of exposure to 
HIV through sex. Cost–beneﬁ  t models 
may be limited by lack of deﬁ  nitive 
transmission parameters in US 
populations and should therefore be 
conducted with appropriate sensitivity 
analyses. Surveys may increase our 
understanding of the acceptability 
of adult male circumcision among 
groups of uncircumcised adult males 
in the US for whom circumcision 
might be recommended (e.g., men 
who have unprotected vaginal or anal 
intercourse with HIV-infected partners, 
or with multiple partners of unknown 
serostatus), and of barriers and 
facilitators to acceptance of adult male 
circumcision, were it recommended 
as an HIV prevention strategy. Given 
recent trial results and international 
consensus that male circumcision is 
efﬁ  cacious, it is important to consider 
ethical questions about whether 
equipoise exists for a US MSM trial, 
and about how to implement trials 
or programs of male circumcision in 
the context of complex cultural and 
religious views about circumcision [27]. 
Evaluating data from basic science, 
modeling, and acceptability surveys 
and addressing ethics questions will 
be important in deciding whether a 
clinical trial to determine the efﬁ  cacy 
of male circumcision among MSM may 
be feasible and appropriate in the US.
Further, recommendations about 
circumcision in newborns or high-
risk adults for the prevention of HIV 
infection cannot be made without a 
more comprehensive discussion of 
other, documented disease prevention 
beneﬁ  ts and risks of circumcision. 
Beneﬁ  ts include reduction in 
acquisition of sexually transmitted 
genital ulcer disease, infant urinary 
tract infections, penile cancer, and 
cervical cancer in female sex partners 
[14,40–43]. Although this is less clear, 
circumcision may also be associated 
with reduced risk of herpes simplex 
virus 2 infection [14]. Risks include 
postoperative infection, damage to the 
penis, excessive bleeding, problems 
with postoperative appearance of 
the penis, and anesthesia-related 
problems [1–3,40]. If it is determined 
that circumcision can play a role in 
preventing HIV transmission and other 
adverse health outcomes in the US, it 
will be important to consider the extent 
to which circumcision is included in 
public and private medical insurance 
beneﬁ  ts. The cost, medical risks, and 
potential beneﬁ  ts of circumcision 
for HIV prevention will need to be 
considered separately for infants, high-
risk heterosexuals, and high-risk MSM. 
Relatively high rates of circumcision 
have prevailed in the US, where 
rates of HIV infection are currently 
relatively low. To the extent that a high 
prevalence of circumcision may have 
hypothetically led to lower HIV rates in 
the US, reducing reimbursement and 
declining rates of the procedure could 
reverse this beneﬁ  cial effect.
To address these scientiﬁ  c and 
policy questions with a broad group 
of stakeholders, the US Centers for 
Disease Control and Prevention 
convened a consultation in April 2007 
to gain diverse input about the public 
health research agenda and to develop 
public health recommendations 
about the role of male circumcision 
for prevention of HIV in the US. 
The summary of the outcomes of the 
consultation will be made available 
later in 2007, via the Centers’ Division 
of HIV/AIDS Prevention Web site 
(http:⁄⁄www.cdc.gov/hiv/).  
Acknowledgments
Author contributions. PSS analyzed the 
data. All authors contributed to writing 
the paper. MLK is part of the Centers for 
Disease Control and Prevention’s workgroup 
addressing male circumcision in the US, and 
helped identify and review the literature 
involved in this paper. TDM contributed to 
the conceptualization of this manuscript, the 
formulation of the ideas, and the writing.
References
1.   Auvert B, Taljaard D, Lagarde E, Sobngwi-
Tambekou J, Sitta R, et al. (2005) Randomized, 
controlled intervention trial of male 
circumcision for reduction of HIV infection 
risk: The ANRS 1265 trial. PLoS Med 2: e298. 
doi:10.1371/journal.pmed.0020298
2.   Bailey RC, Moses S, Parker CB, Agot K, 
Maclean I, et al. (2007) Male circumcision 
for HIV prevention in young men in Kisumu, 
Kenya: A randomised controlled trial. Lancet 
369: 643–656.
3.   Gray RH, Kigozi G, Serwadda D, Makumbi F, 
Watya S, et al. (2007) Male circumcision for 
HIV prevention in men in Rakai, Uganda: A 
randomised trial. Lancet 369: 657–666.
4.   Joint United Nations Programme on HIV/
AIDS (2007) New data on male circumcision 
and HIV prevention: Policy and programme 
implications. Available: http://www.who.
int/hiv/mediacentre/MCrecommendations_
en.pdf. Accessed 21 June 2007.
5.   Williams BG, Lloyd-Smith JO, Gouws E, 
Hankins C, Getz WM, et al. (2006) The 
potential impact of male circumcision on HIV 
in sub-Saharan Africa. PLoS Med 3: e262. 
doi:10.1371/journal.pmed.0030262
6.   Gray RH, Li X, Kigozi G, Serwadda D, 
Nalugoda F, et al. (2007) The impact of male 
circumcision on HIV incidence and cost per 
infection prevented: A stochastic simulation 
model from Rakai, Uganda. AIDS 21: 845–850.
7.   Smith S (2006 October 16) Circumcision 
may help ﬁ  ght AIDS in Africa, but in the US, 
the medical argument is iffy. Boston Globe. 
Available: http:⁄⁄www.boston.com/news/
globe/health_science/articles/2006/10/16/
to_cut_or_not_to_cut/. Accessed 21 June 2007.
8.   Joint United Nations Programme on HIV/
AIDS, World Health Organization (2006) 
AIDS epidemic update. Available: http:⁄⁄www.
unaids.org/en/HIV_data/epi2006/default.asp. 
Accessed 21 June 2007.
9.   McQuillan GM, Kruszon-Moran D, Kottiri BJ, 
Kamimoto LA, Lam L, et al. (2006) Prevalence 
of HIV in the US household population: The 
National Health and Nutrition Examination 
Surveys, 1988 to 2002. J Acquir Immune Deﬁ  c 
Syndr 41: 651–656.
10. US Centers for Disease Control and Prevention 
(2007) HIV/AIDS surveillance report: Cases 
of HIV infection and AIDS in the United 
States and dependent areas, 2005. Volume 
17. Revised edition. Available: http:⁄⁄www.
cdc.gov/hiv/topics/surveillance/resources/
reports/2005report/default.htm. Accessed 10 
July 2007.
July 2007  |  Volume 4  |  Issue 7  |  e223PLoS Medicine  |  www.plosmedicine.org 1166
11. Patterson BK, Landay A, Siegel JN, Flener Z, 
Pessis D, et al. (2002) Susceptibility to human 
immunodeﬁ  ciency virus-1 infection of human 
foreskin and cervical tissue grown in explant 
culture. Am J Pathol 161: 867–873.
12. McCoombe SG, Short RV (2006) Potential 
HIV-1 target cells in the human penis. AIDS 20: 
1491–1495.
13. Donoval BA, Landay AL, Moses S, Agot K, 
Ndinya-Achola JO, et al. (2006) HIV-1 target 
cells in foreskins of African men with varying 
histories of sexually transmitted infections. Am 
J Clin Pathol 125: 386–391.
14. Weiss HA, Thomas SL, Munabi SK, Hayes RJ 
(2006) Male circumcision and risk of syphilis, 
chancroid, and genital herpes: A systematic 
review and meta-analysis. Sex Transm Infect 82: 
101–109.
15. Warner L, Ghanem KG, Newman D, Macaluso 
M, Sullivan P, et al. (2006) Male circumcision 
and risk of HIV infection among heterosexual 
men attending Baltimore STD clinics: An 
evaluation of clinic-based data [presentation]. 
Society for Epidemiologic Research Meeting; 
21–24 June 2006 ; Seattle, Washington, United 
States of America. Available: http:⁄⁄cdc.confex.
com/cdc/std2006/techprogram/P11223.
HTM. Accessed 21 June 2007.
16. Varghese B, Maher JE, Peterman TA, Branson 
BM, Steketee RW (2002) Reducing the risk 
of sexual HIV transmission: Quantifying the 
per-act risk for HIV on the basis of choice of 
partner, sex act, and condom use. Sex Transm 
Dis 29: 38–43.
17. Zuckerman RA, Whittington WL, Celum 
CL, Collis TK, Lucchetti AJ, et al. (2004) 
Higher concentration of HIV RNA in rectal 
mucosa secretions than in blood and seminal 
plasma, among men who have sex with men, 
independent of antiretroviral therapy. J Infect 
Dis 190: 156–161.
18. John-Stewart GC, Nduati RW, Rousseau CM, 
Mbori-Ngacha DA, Richardson BA, et al. 
(2005) Subtype C is associated with increased 
vaginal shedding of HIV-1. J Infect Dis 192: 
492–496.
19. Buchbinder SP, Vittinghoff E, Heagerty 
PJ, Celum CL, Seage GR III, et al. (2005) 
Sexual risk, nitrite inhalant use, and 
lack of circumcision associated with HIV 
seroconversion in men who have sex with men 
in the United States. J Acquir Immune Deﬁ  c 
Syndr 39: 82–89.
20. Kreiss JK, Hopkins SG (1993) The association 
between circumcision status and human 
immunodeﬁ  ciency virus infection among 
homosexual men. J Infect Dis 168: 1404–1408.
21. Grulich AE, Hendry O, Clark E, Kippax S, 
Kaldor JM (2001) Circumcision and male-to-
male sexual transmission of HIV. AIDS 15: 
1188–1189.
22. Marozsan AJ, Moore DM, Lobritz MA, 
Fraundorf E, Abraha A, et al. (2005) 
Differences in the ﬁ  tness of two diverse wild-
type human immunodeﬁ  ciency virus type 1 
isolates are related to the efﬁ  ciency of cell 
binding and entry. J Virol 79: 7121–7134.
23. Schoen E (2005) On circumcision. Berkeley: 
RBR Books. pp. 1–135.
24. Laumann EO, Masi CM, Zuckerman EW 
(1997) Circumcision in the United States. 
Prevalence, prophylactic effects, and sexual 
practice. JAMA 277: 1052–1057.
25. US Centers for Disease Control and 
Prevention (2000) Trends in circumcision 
among newborns. Available: http:⁄⁄www.cdc.
gov/nchs/products/pubs/pubd/hestats/
circumcisions/circumcisions.htm. Accessed 21 
June 2007.
26. Nelson CP, Dunn R, Wan J, Wei JT (2005) The 
increasing incidence of newborn circumcision: 
Data from the nationwide inpatient sample. J 
Urol 173: 978–981.
27. Xu F, Markowitz LE, Sternberg MR, Aral 
SO (2007) Prevalence of circumcision and 
herpes simplex virus type 2 infection in men 
in the United States: The National Health and 
Nutrition Examination Survey (NHANES), 
1999–2004. Sex Transm Dis. E-pub 15 March 
2007.
28. US Centers for Disease Control and Prevention 
(2007) Racial/ethnic disparities in diagnoses 
of HIV/AIDS—33 states, 2001–2005. MMWR 
Morb Mortal Wkly Rep 56: 189–193.
29. Westercamp N, Bailey RC (2007) Acceptability 
of male circumcision for prevention of HIV/
AIDS in sub-Saharan Africa: A review. AIDS 
Behav 11: 341–355.
30. Begley E, Jafa K, Voetsch A, Heffelﬁ  nger 
J, Sullivan PS (2007) Willingness of men 
who have sex with men in the US to be 
circumcised as adults to reduce risk of HIV 
infection [abstract 983]. 14th Conference on 
Retroviruses and Opportunistic Infections; 3–7 
February 2007; Boston, Massachusetts, United 
States of America. Available: http:⁄⁄www.
retroconference.org/2007/Abstracts/28594.
htm. Accessed 21 June 2007.
31. [No authors listed] (1989) American Academy 
of Pediatrics. Report of the Task Force on 
Circumcision. Pediatrics 84: 388–391.
32. [No authors listed] (1999) American Academy 
of Pediatrics. Circumcision policy statement. 
Pediatrics 103: 686–693.
33. [No authors listed] (2005) American Academy 
of Pediatrics. AAP publications retired and 
reafﬁ  rmed. Pediatrics 116: 796.
34. Mansﬁ  eld CJ, Hueston WJ, Rudy M (1995) 
Neonatal circumcision: Associated factors and 
length of hospital stay. J Fam Pract 41: 370–376.
35. National Conference of State Legislatures 
(2006) State health notes: Circumcision 
and infection. Available: http:⁄⁄www.ncsl.
org/programs/health/shn/2006/hl475.htm. 
Accessed 21 June 2007.
36. Stall RD (2006) Re-emerging HIV epidemics 
among MSM in the United States and other 
industrialized nations: Evidence and insight 
[abstract THBS0202]. 16th International AIDS 
Conference; 13–18 August 2006; Toronto, 
Ontario, Canada. Available: http://www.
aids2006.org/pag/PSession.aspx?s=150. 
Accessed 21 June 2007.
37. Sanchez T, Finlayson T, Drake A, Behel 
S, Cribbin M, et al. (2006) Human 
immunodeﬁ  ciency virus (HIV) risk, prevention, 
and testing behaviors—United States, National 
HIV Behavioral Surveillance System: Men who 
have sex with men, November 2003–April 2005. 
MMWR Surveill Summ 55: 1–16.
38. US Centers for Disease Control and Prevention 
(2004) HIV testing survey, 2002. HIV/AIDS 
special surveillance report 5. Available: 
http:⁄⁄www.cdc.gov/hiv/topics/surveillance/
resources/reports/2004spec_no5/default.htm. 
Accessed 21 June 2007.
39. Espinoza L, Hall HI, Hardnett F, Selik RM, 
Ling Q, et al. (2007) Characteristics of persons 
with heterosexually acquired HIV infection, 
United States 1999–2004. Am J Public Health 
97: 144–149.
40. Moses S, Bailey RC, Ronald AR (1998) Male 
circumcision: Assessment of health beneﬁ  ts 
and risks. Sex Transm Infect 74: 368–373.
41. Alanis MC, Lucidi RS (2004) Neonatal 
circumcision: A review of the world’s oldest and 
most controversial operation. Obstet Gynecol 
Surv 59: 379–395.
42. Fergusson DM, Boden JM, Horwood LJ 
(2006) Circumcision status and risk of sexually 
transmitted infection in young adult males: 
An analysis of a longitudinal birth cohort. 
Pediatrics 118: 1971–1977.
43. Diseker RA III, Peterman TA, Kamb ML, Kent 
C, Zenilman JM, et al. (2000) Circumcision 
and STD in the United States: Cross sectional 
and cohort analyses. Sex Transm Infect 76: 
474–479.
July 2007  |  Volume 4  |  Issue 7  |  e223